Nature briefing examines how billionaire philanthropists are reshaping biomedical research funding
A Nature briefing reports that as more AI companies prepare to go public, the number of ultra-wealthy philanthropists funding biomedical science in the US is expected to grow. These donors tend to back higher-risk, personally meaningful projects with fewer conditions than government agencies typically impose, according to the briefing.